Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma

被引:9
|
作者
Rade, Michael [1 ]
Grieb, Nora [2 ,3 ]
Weiss, Ronald [1 ,4 ]
Sia, Jaren [5 ]
Fischer, Luise [2 ]
Born, Patrick [2 ]
Boldt, Andreas [4 ]
Fricke, Stephan [4 ]
Franz, Paul [4 ]
Scolnick, Jonathan [5 ]
Venkatraman, Lakshmi [5 ]
Xu, Stacy [5 ]
Kloetzer, Christina [2 ]
Heyn, Simone [2 ]
Kubasch, Anne Sophie [2 ]
Baber, Ronny [6 ,7 ]
Wang, Song Yau [2 ]
Bach, Enrica [2 ]
Hoffmann, Sandra [2 ]
Ussmann, Jule [2 ]
Schetschorke, Birthe [2 ]
Hell, Saskia [2 ]
Schwind, Sebastian [2 ]
Metzeler, Klaus H. [2 ]
Herling, Marco [2 ]
Jentzsch, Madlen [2 ]
Franke, Georg-Nikolaus [2 ]
Sack, Ulrich [4 ]
Koehl, Ulrike [1 ,4 ]
Platzbecker, Uwe [2 ]
Reiche, Kristin [1 ,4 ,8 ]
Vucinic, Vladan [2 ]
Merz, Maximilian [2 ]
机构
[1] Fraunhofer Inst Cell Therapy & Immunol IZI, Leipzig, Germany
[2] Univ Hosp Leipzig, Dept Hematol Cellular Therapy & Hemostaseol, Leipzig, Germany
[3] Univ Hosp Leipzig, Innovat Ctr Comp Assisted Surg, Leipzig, Germany
[4] Univ Hosp Leipzig, Inst Clin Immunol, Leipzig, Germany
[5] Singleron Biotechnol, Cologne, Germany
[6] Univ Hosp Leipzig, Inst Lab Med Clin Chem & Mol Diagnost, Leipzig, Germany
[7] Univ Leipzig, Leipzig Med Biobank, Leipzig, Germany
[8] Ctr Scalable Data Analyt & Artificial Intelligence, Leipzig, Germany
关键词
THERAPY;
D O I
10.1038/s43018-024-00763-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Markers that predict response and resistance to chimeric antigen receptor (CAR) T cells in relapsed/refractory multiple myeloma are currently missing. We subjected mononuclear cells isolated from peripheral blood and bone marrow before and after the application of approved B cell maturation antigen-directed CAR T cells to single-cell multiomic analyses to identify markers associated with resistance and early relapse. Differences between responders and nonresponders were identified at the time of leukapheresis. Nonresponders showed an immunosuppressive microenvironment characterized by increased numbers of monocytes expressing the immune checkpoint molecule CD39 and suppressed CD8+ T cell and natural killer cell function. Analysis of CAR T cells showed cytotoxic and exhausted phenotypes in hyperexpanded clones compared to low/intermediate expanded clones. We identified potential immunotherapy targets on CAR T cells, like PD1, to improve their functionality and durability. Our work provides evidence that an immunosuppressive microenvironment causes resistance to CAR T cell therapies in multiple myeloma. Merz and colleagues perform single-cell multiomic analysis of mononuclear cells isolated from individuals receiving BCMA-directed CAR T cell therapy for myeloma and show that nonresponders are characterized by an immune-suppressive microenvironment.
引用
收藏
页码:1318 / 1333
页数:29
相关论文
共 50 条
  • [41] Allogeneic chimeric antigen receptor T cells for children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
    Locatelli, Franco
    del Bufalo, Francesca
    Quintarelli, Concetta
    HAEMATOLOGICA, 2024, 109 (06) : 1689 - 1699
  • [42] Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
    Drent, Esther
    Groen, Richard W. J.
    Noort, Willy A.
    Themeli, Maria
    van Bueren, Jeroen J. Lammerts
    Parren, Paul W. H. I.
    Kuball, Jurgen
    Sebestyen, Zsolt
    Yuan, Huipin
    de Bruijn, Joost
    van de Donk, Niels W. C. J.
    Martens, Anton C. M.
    Lokhorst, Henk M.
    Mutis, Tuna
    HAEMATOLOGICA, 2016, 101 (05) : 616 - 625
  • [43] Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma
    Wang, Ying
    Cao, Jiang
    Gu, Weiying
    Shi, Ming
    Lan, Jianping
    Yan, Zhiling
    Jin, Lai
    Xia, Jieyun
    Ma, Sha
    Liu, Yang
    Li, Hujun
    Pan, Bin
    Chen, Wei
    Fei, Xiaoming
    Wang, Chunling
    Xie, Xiaobao
    Yu, Liang
    Wang, Gang
    Li, Huizhong
    Jing, Guangjun
    Cheng, Hai
    Zhu, Feng
    Sun, Haiying
    Sang, Wei
    Li, Depeng
    Li, Zhenyu
    Zheng, Junnian
    Xu, Kailin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (20) : 2246 - +
  • [44] Chimeric antigen receptor T-cells for B-cell malignancies
    Lichtman, Eben I.
    Dotti, Gianpietro
    TRANSLATIONAL RESEARCH, 2017, 187 : 59 - 82
  • [46] Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma
    Wu, Jiaying
    Cao, Yang
    Zhang, Qi
    Liu, Wanying
    Zhou, Xiaoxi
    Ming, Xi
    Meng, Fankai
    Zhang, Yicheng
    Li, Chunrui
    Huang, Liang
    Wei, Jia
    Zheng, Miao
    Zhang, Shangkun
    Zhang, Tongcun
    Zhu, Xiaojian
    Wang, Na
    Wang, Jue
    Wang, Gaoxiang
    Zhou, Jianfeng
    Liu, Bo
    Xiao, Yi
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [47] Specific Targeting of Multiple Myeloma by Dual Split-signaling Chimeric Antigen Receptor T cells Directed against CD38 and CD138
    van der Schans, Jort J.
    Wang, Ziyu
    van Arkel, Jennemiek
    van Schaik, Thijs
    Katsarou, Afroditi
    Ruiter, Ruud
    Baardemans, Thomas
    Yuan, Huipin
    de Bruijn, Joost
    Zweegman, Sonja
    van de Donk, Niels W. C. J.
    Groen, Richard W. J.
    Themeli, Maria
    Mutis, Tuna
    CLINICAL CANCER RESEARCH, 2023, 29 (20) : 4219 - 4229
  • [48] Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase II Trial
    Xia, Jieyun
    Li, Hujun
    Yan, Zhiling
    Zhou, Dian
    Wang, Ying
    Qi, Yuekun
    Cao, Jiang
    Li, Depeng
    Cheng, Hai
    Sang, Wei
    Zhu, Feng
    Sun, Haiying
    Chen, Wei
    Qi, Kunming
    Yan, Dongmei
    Qiu, Tingting
    Qiao, Jianlin
    Yao, Ruosi
    Liu, Yang
    Wang, Xue
    Zhang, Yanlei
    Peng, Shuixiu
    Huang, Chih-Hua
    Zheng, Junnian
    Li, Zhenyu
    Chang, Alex H. H.
    Xu, Kailin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14) : 2583 - +
  • [49] Chimeric antigen receptor T-cell treatment patterns in relapsed or refractory large B-cell lymphoma
    Seyedin, Roxanna
    Snider, Julia T.
    Rajagopalan, Krithika
    Wade, Sally W.
    Gergis, Usama
    FUTURE ONCOLOGY, 2023, 19 (22) : 1535 - 1547
  • [50] Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells
    An, Na
    Hou, Yun Nan
    Zhang, Qiao Xia
    Li, Ting
    Zhang, Qiong Li
    Fang, Cheng
    Chen, Huan
    Lee, Hon Cheung
    Zhao, Yong Juan
    Du, Xin
    MOLECULAR PHARMACEUTICS, 2018, 15 (10) : 4577 - 4588